AN
Alto Neuroscience, Inc.
ANRO · NYSE
$35.80 +0.70% (+$0.25)
1M +26.58%
Market Cap $1.26B
P/E Ratio -
Div. Yield -
ROE 46.46%
Piotroski F-Score Weak
2/9Valuation
28 /100
Expensive P/B 5.73x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
37 /100
Average ROIC 18.43%
ROE 46.46%
ROA 33.16%
Debt
69 /100
Low Debt/Equity 0.03x
Current ratio 14.85x
Int. coverage -36.26x
Stability
44 /100
Moderate Beta 1.09x
EPS volatility 49.23%
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o ANRO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Amit Etkin
Employees
68
Headquarters
Mountain View
Nadchodzące wydarzenia
11 LIS
Earnings
Upcoming earnings report